Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | FECH | P22830 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24569929 | 0.90 | MAPK1 (0.53) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL29887883 | 0.90 | MAPK1 (0.53) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL24167224 | 0.86 | EGFR (0.55) | EGFRERBB2MAPT | |
| SCHEMBL4866251 | 0.85 | EGFR (0.67) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL24167628 | 0.84 | MAPT (0.56) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL24167264 | 0.84 | EGFR (0.58) | EGFRERBB2ERBB4FECHCDK8 | |
| SCHEMBL2990157 | 0.82 | EGFR (0.62) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL29888120 | 0.81 | ERBB2 (0.41) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL24569631 | 0.81 | ERBB2 (0.41) | EGFRERBB2LMNAMAPTHTT | |
| SCHEMBL24168161 | 0.81 | ERBB2 (0.44) | EGFRERBB2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | EGFR 6/4885ERBB2 1/4885LMNA 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.